Disease · HP_0000360

Tinnitus

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Tinnitus. Diseases, record HP_0000360. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000360

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Tinnitus
Open Targets ID: HP_0000360
Other names: Ringing in ears, Ringing in the ears
Highest stage of its drugs: Approval, for 1 of its 43 drugs, from TTD

Source Open Targets

Drugs43

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SULODEXIDE	CHEMBL2108086		Approval	TTD	1	0	0	Drugs and targets
ESKETAMINE HYDROCHLORIDE	CHEMBL2364609	Small molecule	Phase 3	ClinicalTrials.gov and TTD	5	4	4	Drugs and targets
NERAMEXANE MESYLATE	CHEMBL2106798	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
NERAMEXANE	CHEMBL2110954	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
OXYTOCIN	CHEMBL395429	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CAROVERINE	CHEMBL1729803	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
GABAPENTIN	CHEMBL940	Small molecule	Phase 2/3	ClinicalTrials.gov	3	3	3	Drugs and targets
GACYCLIDINE	CHEMBL3989791	Small molecule	Phase 2	ClinicalTrials.gov	4	3	3	Drugs and targets
EBSELEN	CHEMBL51085	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
AMITRIPTYLINE	CHEMBL629	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 43

See all 43 drugs

Targets91

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GRIN1	Glutamate [NMDA] receptor	5	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/2902	Drugs and targets
GRIN2A	Glutamate [NMDA] receptor	5	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/2903	Drugs and targets
GRIN2B	Glutamate [NMDA] receptor	5	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/2904	Drugs and targets
GRIN2C	Glutamate [NMDA] receptor	5	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/2905	Drugs and targets
GRIN2D	Glutamate [NMDA] receptor	5	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/2906	Drugs and targets
GRIN3A	Glutamate [NMDA] receptor	5	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/116443	Drugs and targets
GRIN3B	Glutamate [NMDA] receptor	5	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/116444	Drugs and targets
NR3C1	Glucocorticoid receptor	4	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
DRD2	D(2) dopamine receptor	3	D2-like dopamine receptor antagonist; Dopamine D2 receptor antagonist; Dopamine receptor antagonist	Phase 2	https://conductscience.org/library/genes/1813	Drugs and targets
GABRA1	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 2	https://conductscience.org/library/genes/2554	Drugs and targets

1 to 10 of 91

See all 91 targets

Trials44

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01803646	AM-101 in the Treatment of Acute Tinnitus 2	Phase 3	343	2018-05-29	Tinnitus	ESKETAMINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01934010	AM-101 in the Treatment of Post-Acute Tinnitus 1	Phase 3	260	2018-03-09	Tinnitus	ESKETAMINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT04829214	OTO-313 in Subjects With Unilateral Subjective Tinnitus	Phase 2	153	2023-01-06	Subjective Tinnitus	GACYCLIDINE	Its record names the disease	ClinicalTrials.gov
NCT03918109	OTO-313 in Subjects With Subjective Tinnitus	Phase 1/2	43	2022-12-23	Tinnitus, Subjective	GACYCLIDINE	Its record names the disease	ClinicalTrials.gov
NCT04210310	High Dose Oxytocin Nasal Spray for Treatment of Tinnitus	Phase 3	33	2022-10-05	Tinnitus	OXYTOCIN	Its record names the disease	ClinicalTrials.gov
NCT05645432	An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus	Phase 2	10	2024-12-12	Tinnitus	BREXANOLONE	Its record names the disease	ClinicalTrials.gov
NCT00591019	Use of Modafinil in the Treatment of Tinnitus	Phase 1	7	2011-05-09	Tinnitus	MODAFINIL	Its record names the disease	ClinicalTrials.gov
NCT02040194	AM-101 in the Treatment of Acute Tinnitus 3	Phase 3	893		Tinnitus	ESKETAMINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00827008	Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus	Phase 3	821		Subjective Tinnitus	NERAMEXANE MESYLATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00955799	Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus	Phase 3	455		Subjective Tinnitus	NERAMEXANE	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 44

See all 44 trials

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
AM-101 0.87 mg/mL Gel vs Placebo Gel: deaths from any cause	0 of 201	0 of 135	336	NCT01803646	Trial comparisons
AM-101 0.87 mg/mL Gel vs Placebo Gel: serious adverse events	5 of 201	1 of 135	336	NCT01803646	Trial comparisons
OTO-313 Full Analysis Set vs Placebo Full Analysis Set: Percentage of Tinnitus Functional Index (TFI) Responders at Weeks 4 and at Week 8	20 of 77	27 of 76	153	NCT04829214	Trial comparisons
OTO-313 Safety Analysis Set vs Placebo Safety Analysis Set: deaths from any cause	0 of 77	0 of 76	153	NCT04829214	Trial comparisons
OTO-313 Safety Analysis Set vs Placebo Safety Analysis Set: serious adverse events	2 of 77	0 of 76	153	NCT04829214	Trial comparisons
OTO-313 Safety Analysis Set vs Placebo Safety Analysis Set: Otoscopic Examinations - Presence of Perforation in the Treated Ear at Week 16 (Final Visit)	0 of 77	0 of 74	151	NCT04829214	Trial comparisons
High-dose Intranasal Oxytocin vs Nasal Spray: deaths from any cause	0 of 32	0 of 1	33	NCT04210310	Trial comparisons
High-dose Intranasal Oxytocin vs Nasal Spray: serious adverse events	1 of 32	0 of 1	33	NCT04210310	Trial comparisons

Papers from its trials33

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34768526	RESULT	1	PubMed
34282564	RESULT	1	PubMed
32471239	RESULT	1	PubMed
31842394	RESULT	1	PubMed
31042571	RESULT	1	PubMed
30538616	RESULT	1	PubMed
30469326	RESULT	1	PubMed
30261653	RESULT	1	PubMed
30058696	RESULT	1	PubMed
30015600	RESULT	1	PubMed

1 to 10 of 33

See all 33 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0000360

GET https://conductscience.org/api/diseases/v1/HP_0000360/drugs?page=2

API reference For AI assistants